32 results about "Distinctin" patented technology

The application discloses a preparation method of an immune protein extract of colostrum with tumor inhibition efficacy, and comprises the following steps: (1) raw material selection; (2) flocculation of casein; (3) sugar removal; (4) ultrafiltration membrane filtration; (5) directional hydrolysis; (6) cation exchange resin adsorption; (7) desalination; and (8) freeze drying. The extract of the application is rich in hydrophobic amino acid and alkaline amino acid hydrolysis fragments of the immune protein of colostrum, and has stronger antioxidant, immune enhancement and tumor inhibition activities. Different from common immune proteins of colostrum, the extract plays the anti-tumor activity as a result of the combined action of its double effects of immune enhancement and tumor cell growth inhibition.

The invention provides a prawn disease-oriented intestinal tract key metabolite design method and device, and relates to the technical field of strategy optimizing.The prawn disease-oriented intestinal tract key metabolite design method comprises the steps that prawn intestinal tract metabolite data are obtained, a random forest model distinguishes prawn health conditions through intestinal tract metabolite, and indication intestinal tract metabolite for distinguishing the health conditions is determined; the importance of the distinguishing metabolites is quantified through an MDA algorithm, and the most important distinguishing metabolite combination is screened; and distinguishing the metabolite and converting the metabolite concentration into a weighted undirected network, obtaining the feature vector centrality of each metabolite in the molecular ecological network, and determining a key metabolite. According to the invention, the random forest and the molecular ecological network are combined to identify key metabolites in a disease state, and the relative importance of each variable to a classification result is quantified. Meanwhile, the proportion of each key metabolite is determined by tracing back to healthy prawn intestinal tracts, and diseases are prevented and controlled symptomatically by compensating the combination of the inhibited key metabolite in the disease prawns.

The invention belongs to the technical field of biology, relates to a zearalenone degrading enzyme, and particularly relates to a bacillus subtilis source zearalenone degrading enzyme, an engineering strain thereof and an enzyme preparation prepared from the bacillus subtilis source zearalenone degrading enzyme. Compared with the known zearalenone degrading enzyme, the zearalenone degrading enzyme not only has obvious structure and sequence differences, but also shows an excellent degrading effect at low concentration. The lactone hydrolase derived from bacillus is found for the first time, and the biological resource basis of zearalenone degrading enzyme is expanded. The enzyme not only has significant difference from other degrading enzymes in structure, but also shows unique characteristics in degradation mechanism. The capability of efficiently degrading zearalenone shows that the bacillus subtilis has a wide application prospect in the fields of agriculture, food industry and the like. In addition, the invention also covers the structure of a degradation product generated by the zearalenone enzyme, and provides a new perspective for understanding a zearalenone degradation mechanism.

The invention provides an application of ginseng oil body in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of ginseng seed oil. The detection shows that the oil core structure of the ginseng oil body mainly consists of oleic acid and linoleic acid, and is different from the triglyceride core of the oil body obtained from the existing oil crops. Through lipidomics detection and analysis, the phospholipid monomolecular layer has 335 phospholipids (positive ion mode) and 269 phospholipids (negative ion mode). Through proteomics detection and analysis, 24 kinds of Panax proteins are identified. The condition that the oil core of the ginseng oil body contains protopanaxatriol (PPT) is identified through high performance liquid chromatography-high resolution mass spectrometry. In-vitro detection shows that the ginseng oil body has anti-inflammatory and anti-oxidation effects.

The application discloses a kind of recombinant Pichia pastoris for indirectly surface display PETase protein, comprising: (1) 3×IM7-SED1 fusion protein is expressed heterologously in Pichia pastoris GS115, and constructs IM7 yeast.(2)CL7-PETase fusion protein is expressed heterologously in Escherichia coli BL21 (DE3), and constructs CL7-PETase protein.(3)IM7 yeast and CL7-PETase protein are combined, and the surface display of PETase protein on Pichia pastoris is realized.The construction method of indirect surface display used in the application overcomes the disadvantage of insufficient expression of direct surface display system, and compared with free enzyme, has the characteristics of high stability, easy separation and recovery, controllable continuous operation, simple process, and the surface display enzyme is different from traditional physical or chemical immobilization method.For PET rigid substrate, surface display enzyme can more fully and effectively contact with substrate, maximum catalysis substrate, and can be used as whole-cell catalyst in the application of PET plastic degradation.

The invention relates to an InDel molecular marker related to immune traits of Landaise geese and application of the InDel molecular marker, and belongs to the technical field of molecular markers. The InDel molecular marker provided by the invention is located in a full-length sequence of a CNTFR gene as shown in SEQ ID No.1, and insertion of a single base T exists at the 165833rd site. The InDel molecular marker disclosed by the invention can be used for quickly and accurately distinguishing the high / low ratio of heterophilic granulocytes / lymphocytes of the Landaise geese, has the advantages of simplicity and convenience in operation and reliable result, and provides an effective molecular basis for directional breeding of immune-related traits of the Landaise geese.

Analogues of PYY differing from native human PYY by substitution of Ser23 with Ala23, Glu23, Lys23, Gln23 or AIB23. Further optional features include substitutions at further positions, loss of the Tyr1 residue of native human PYY and amidation of the C-terminus. Suitable for use as pharmaceuticals for treating and preventing disorders, in particular diabetes and obesity.

A method of determining a health status of an individual, the method comprising the steps of assaying a biological sample from the individual for the positive expression of SAA1 and / or SAA2, and wherein the positive expression of the SAA1 and / or SAA2 above or below a threshold expression level in a control sample correlates with the health status of the individual.

The invention discloses an InDel molecular marker for identifying the elongation capacity of mesocotyl in rice, application and a method. The nucleotide sequence of the InDel marker is as shown in SEQ ID No. 4; the molecular marker is located at the 981 site to the 2040 site of a nucleotide sequence of SEQ ID No. 1 and is insertion and deletion of 1060 bp; the primer pair for detecting the InDel marker comprises a forward primer with a nucleotide sequence as shown in SEQ ID No. 2 and a reverse primer with a nucleotide sequence as shown in SEQ ID No. 3. The primer designed by the invention can effectively amplify specific gene segments of rice, and the specific gene segments are distinguished through agarose gel electrophoresis, so that mesocotyl length genotypes of different rice germplasms can be effectively distinguished, and identification of target genes in rice germplasm resources and breeding progenies can be conveniently and quickly realized; the labor cost is greatly reduced, the time is saved, and a foundation is laid for rice breeding work.

The present invention discloses a variant D-allulose 3-epimerase (DAEase) that is distinguished from a wild-type DAEase derived from Spirochaetales bacterium (spDAEase) by at least one amino acid sequence variation comprising substitution of an 5 amino acid residue corresponding to position 69, 119, 138, 175, 203, 208, 229, 240, or 265 of SEQ ID NO. 1; or a variant DAEase that is distinguished from a wild-type DAEase derived from Clostridium cellulolyticum (ccDAEase) by an amino acid sequence variation comprising substitution of an amino acid at position 46 and / or a truncation of C-terminal end of in SEQ ID NO. 2.

The invention relates to siRNA as well as a conjugate and application thereof, and belongs to the technical field of molecular biology and biological medicine. The siRNA comprises a positive-sense strand and an antisense strand. The conjugate comprises an aptamer and siRNA (small interfering Ribonucleic Acid). The siRNA and the conjugate provided by the invention are good in targeting property and high in safety, enter cancer cells (such as liver cancer cells) without the help of an exogenous transfection agent, and realize efficient knock-down of an immune checkpoint Nectin-2, so that the anti-tumor reaction of T cells is activated, and the siRNA and the conjugate are used for precise immunotherapy of tumors (such as liver cancer). The conjugate provided by the invention can be autonomously delivered to tumor cells without a transfection agent, quickly enters cytoplasm of the tumor cells without the help of lipidosome, polymer or viral vector, and generates a functional effect. The delivery strategy is high in safety, has unique practical value, and is different from a current mainstream delivery system in the RNA interference field.

This invention relates to the field of veterinary biological products, specifically to a live attenuated strain of Brucella brucellosis RB39, its applications, vaccines, antigens, and kits. The live attenuated Brucella brucellosis RB39 of this invention can be used to prepare a highly safe vaccine that can be injected into pregnant animals and provides good immunoprotection. Furthermore, this vaccine is suitable for immunization of multiple animal species. In addition, based on the live attenuated Brucella brucellosis RB39 of this invention, an antigen can be prepared to identify Brucella brucellosis antibodies, effectively distinguishing between vaccine immunization and natural infection, providing a scientific basis for brucellosis prevention and control.

The present invention relates to a new variant of EPO. In this study, the inventors identified a particular EPO differing from kidney-type EPO due to a different glycosylation pattern in patients with different diseases (for example idiopathic erythrocytosis, liver / kidney disorder, tumors...). This new EPO is similar to pre-term newborn EPO produced by the liver that differs from the normal EPO produced from renal interstitial cells due to different post-translational modifications (glycosylations). This new EPO shows an increased biological activity via activation of the EPO receptor (EPOR), that can explain the origin of erythrocytosis. The detection of this specific liver-like EPO could be used as a diagnostic tool to better adapt and follow the treatments of erythrocytosis patients or in other diseases associated with the overproduction of red blood cells. Thus, the invention relates to a specific EPO protein which differs from the EPO with kidney-type glycosylation pattern.

The invention belongs to the technical field of microbial fermentation, and particularly relates to a novel bacillus velezensis strain as well as a separation and screening method and application thereof. According to the invention, an enterobacter strain which is different from spores and produces tetramethylpyrazine is excavated. According to the invention, a bacillus velezensis 17 with high yield of tetramethylpyrazine is separated and screened from yeast for making hard liquor and fermented grains, and the bacillus velezensis 17 can grow and ferment in solid culture media such as wheat, mouldy bran, five grains and the like at the same time and can produce various pyrazines. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC) on September 11, 2025, the preservation number is CGMCC No.35896, the preservation address is Institute of Microbiology, Chinese Academy of Sciences, 3 #, 1 # yard, West Beichen Road, Chaoyang District, Beijing, the postcode is 100101, and the classification name is Bacillus velezensis. The strain provided by the invention can adapt to a plurality of common fermented grain substrates, and shows good industrial adaptability and stability, so that the strain has a wide application prospect in white spirit brewing.

The invention belongs to the field of medicines, and particularly relates to application of Chinese torreya exosome nano-vesicles in preparation of medicines for treating or improving ulcerative colitis. The invention discloses a traditional medicine which discovers that XFEV not only can obviously reduce proinflammatory factors TNF-alpha and IL-6 and improve an anti-inflammatory factor IL-10, but also can repair a colonic mucosa crypt structure and enhance an intestinal barrier function, and is inferred to indirectly resist inflammation by regulating intestinal flora and is different from a single-mechanism traditional medicine. A plant exosome preparation process is optimized, uniform particles are obtained by combining differential centrifugation with sucrose gradient purification, the curative effect of XFEV delivered by an embedding method is proved to be remarkably superior to that of simple mixing, the targeting and protective advantages of the exosome as a natural carrier are highlighted, and a low-toxicity and high-efficiency new strategy is provided for UC treatment.

The present disclosure provides for endonuclease enzymes having distinguishing domain features, as well as methods of using such enzymes or variants thereof.

The invention discloses a library building method for detecting G-quadruplex structures in oocytes, early embryos and trace cells, and belongs to the technical field of whole genome immunoprecipitation library building. The DNA G-quadruplex structure provided by the invention is a DNA secondary structure which is different from a classic double-helix structure; g-quadruplex structure abnormity can damage telomere stability, genome stability, transcriptional activity and the like; this is an important reason for poor ovum quality and embryonic development retardation. The method provided by the invention can be used for evaluating the quality of the ova of the infertile women and judging reasons causing immaturity of the ova; abnormal enrichment of in-vivo and in-vitro development arrest embryo whole genome G-quadruplex is detected and can be used as an important index for screening reasons causing embryonic development retardation; the method can be used for guiding whether corresponding clinical patients are suitable for a series of assisted reproductive technologies (ART) such as in vitro fertilization-embryo transfer (IVF-ET) and the like.

The invention discloses a pig STING protein K61R mutant and application thereof, the mutant is obtained by mutating the 61th lysine of the pig STING protein into arginine, and the amino acid sequence of the pig STING protein is as shown in SEQ ID NO. 1. According to the invention, the species-specific key site K61 of the pig STING protein is identified for the first time, the site is unique to pigs and is different from other species, and by regulating the protein stability and downstream signal transduction, a key negative regulation effect on virus replication of ASFV, PRV, HSV-1 and the like is achieved; meanwhile, the K61 site can be directly used as a core molecular marker and a targeting site for pig antiviral breeding, and important support is provided for improving the research efficiency of disease-resistant breeding.

The invention relates to a recombinant cosmile of a duck adenovirus B2 reverse genetic operating system and application of the recombinant cosmile, the recombinant cosmile is a recombinant cosmile BG18FOS-2 and is constructed by using duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19, the duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: V202568. Compared with a duck adenovirus B2 strain BGMH, the recombinant cosmid BG18FOS-2 sequence has the differences as shown in SEQ ID No.1-2, a deletion region located between a gene ORF20 and a gene ORF53 and the like. The recombinant cosmile can successfully rescue a virus with the same biological characteristics as the duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19, and a reverse genetic operating system containing the recombinant cosmile is successfully constructed.

The present invention relates to monoclonal antibodies that target collagen type XIX and to the sequences of the complementarity-determining regions distinguishing the monoclonal antibodies. Also, the present invention relates to immunoassays and to kits employing the antibodies. The assays of the invention are used in the diagnosis and monitoring of cancer.

The invention belongs to the technical field of biological medicine, and particularly relates to an intestinal fungus microorganism model for noninvasive diagnosis of an atrial fibrillation patient and application of the intestinal fungus microorganism model. The invention provides an intestinal tract fungal microorganism model (fungal microorganism distinguishing model) for distinguishing atrial fibrillation patients and non-atrial fibrillation patients, which consists of 15 fungal microorganism genes as shown in SEQ ID NO: 1-15, and the fungal microorganism genes are enriched in human intestinal tracts. The intestinal fungus microbial gene distinguishing model disclosed by the invention realizes good distinguishing ability between atrial fibrillation patients and non-atrial fibrillation patients, and also verifies the feasibility, applicability and universality of the distinguishing model in different regions in China.

The invention belongs to the field of medical detection, and mainly relates to a chemiluminiscence detection kit based on a nucleic acid aptamer and a preparation method of the chemiluminiscence detection kit. The chemiluminiscence detection kit prepared by the invention comprises reagents M and R. The reagent M comprises a magnetic particle coupling recognition molecule which can be called as a capture probe; the reagent R comprises a chemiluminescent marker coupled recognition molecule which can be called as a chemiluminescent probe; the recognition molecules are aptamers or antibodies, and the recognition molecules in the reagent M and the reagent R are not antibodies at the same time. The chemiluminescence detection kit combines convenient detection and analysis of a magnetic particle chemiluminescence method and high specificity and high affinity of the aptamer, and can timely and accurately detect various proteins. Different from a capture probe and a chemiluminescent probe which are constructed by using a protein antibody in the market, the kit overcomes the problems of poor stability, difficulty in modification, high production cost and the like of the protein antibody, and is of great significance in the field of immunodetection.

The present application relates to an InDel molecular marker related to the immune traits of Landes geese and an application thereof, and belongs to the technical field of molecular markers. CNTFR The InDel molecular marker in the present application is located in the full-length sequence of SEQ ID No. 1, and a single-base T insertion exists at the 165833th position. The InDel molecular marker of the present application can be used to quickly and accurately distinguish the high / low ratio of heterophil granulocyte / lymphocyte of Landes geese, has the advantages of simple operation and reliable results, and provides an effective molecular basis for the directional selection of the immune-related traits of Landes geese.

This application discloses a nuclear localization signal AoNLS and its application in enhancing CRISPR / Cas9 editing in zebrafish. The nuclear localization signal AoNLS is derived from the zebrafish proteome. Through bioinformatics mining and functional screening, a structurally unique amino acid, KRKREAE, was identified, with its amino acid sequence shown in SEQ ID NO:1. This sequence is composed of both basic and acidic amino acids, and its mode of action differs from the single charge-driven mechanism of traditional NLS, achieving a breakthrough improvement in nuclear input efficiency. The Pcs2-AoNLS-GFP system, constructed by fusing AoNLS with GFP protein, showed a 1.56-fold increase in nuclear input efficiency in zebrafish embryos compared to the traditional SV40 NLS. Simultaneously, the Pcs2-AoNLS-Cas9 system, constructed by fusing AoNLS with Cas9 protein, significantly enhanced the editing efficiency of the Stat3 and Amh target genes by 1.72 times and 1.82 times, respectively, compared to the Pcs2-SV40 NLS-Cas9 gene editing system. The AoNLS sequence provided in this application is short and highly efficient, and can be used as a core component of the next-generation gene editing tool nuclear delivery system, with good application prospects in the fields of aquaculture breeding and developmental biology research.

The present application relates to a detection method and kit for distinguishing CAEBV and EBV positive or negative PTCL. The present application provides the use of a detection reagent of a biomarker in the preparation of a composition or kit for distinguishing chronic active Epstein-Barr virus infection (CAEBV), Epstein-Barr virus positive peripheral T cell lymphoma (EBV+ PTCL) and Epstein-Barr virus negative peripheral T cell lymphoma (EBV- PTCL), wherein the biomarker comprises any 1, 2, 3, 4, 5 of the FAS, SELP, LY86, GZMB and CCL7 genes, preferably a combination comprising all 5 of them. Compared with traditional clinical observation, pathological biopsy and in situ hybridization, the present application has higher disease specificity and sensitivity, and can provide molecular basis for early clinical treatment and drug intervention.

The present disclosure provides for engineered base editing system comprising endonuclease enzymes having distinguishing domain features, as well as methods of using such enzymes or variants thereof, wherein the engineered base editing system comprises a base editor and an engineered guide polynucleotide configured to form a complex with an endonuclease of the base editor and comprises a spacer sequence that hybridizes to a target nucleic acid sequence.

A mass spectrometry control device includes a deriver that derives, based on a set of allergens that are detectable without being distinguished from one another among a plurality of allergens to be detected and data that indicates a plurality of peptides produced by subjecting each allergen to a cleavage process, first peptides produced in common when the plurality of allergens included in the set are subjected to the cleavage process and at least one of parameters for detecting the first peptides, and a setter that sets a condition of mass spectrometry to detect at least one of the first peptides.

The invention relates to an application of an alpha-actin-co-actin 3 protein gene as a gene modification target in improving the production performance of bovine animals. Further provided is a mutated bovine alpha-actin-3 protein gene or fragment thereof, the mutated bovine alpha-actin-3 protein gene comprising a modified chromosome sequence in at least one allele of a gene encoding an alpha-actin-3 protein, wherein the modified chromosomal sequence partially or completely compromises the ability of the gene to encode the protein. The bovine animal containing the mutated bovine alpha-actin-co-actin-3 protein gene or fragment thereof almost retains all characteristics of the wild-type bovine animal, and the difference is that the number and the cross-sectional area of II-type muscle fibers are reduced and the proportion of I-type muscle fibers is increased, so that the efficiency of a feeding farm is improved, the meat quality is improved, and emission is reduced.

An antibody specifically binding to CCR8, an antibody fragment, an antigen-binding part thereof, and the related use. The anti-CCR8 antibody has a differentiation advantage of targeting CCR8, thereby providing a medication choice and therapeutic regimen for tumor patients.

The application belongs to the field of genetic engineering, and particularly relates to a recombinant blue tongue virus which fuses and expresses a tetracysteine (TC) tag on NS2 protein and a construction method. The application inserts a TC tag at the C terminal (after the 354th amino acid) of the non-structural protein NS2 of a wild type blue tongue virus to construct a recombinant blue tongue virus BTV1-NS2-354TC. The recombinant blue tongue virus has no obvious difference from the wild type blue tongue virus in biological characteristics, and the NS2 protein expressed by the recombinant blue tongue virus and carrying the TC tag can be dyed by a double arsenic dye (FlAsH-EDT2), shows green fluorescence under a fluorescence microscope, and can be used for visual quantitative detection of BTV infection and positioning and tracing research of the NS2 protein.